Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache

Table 4 Base case^a cost-effectiveness analysis

Treatment group	Mean cost, €	Mean QALY	ICER^b
nVNS + SoC	7096.96	0.607	nVNS dominant over SoC^c
SoC alone	7511.35	0.522	nVNS dominant over SoC^c

Abbreviations: ICER incremental cost-effectiveness ratio, nVNS non-invasive vagus nerve stimulation, QALY quality-adjusted life-year, SoC standard of care
Probabilistic estimates are based on mean results across all Monte Carlo simulations [21]
^aIn the base case, subjects in the nVNS + SoC group who responded through the extension phase were assumed to maintain response
^bThe expense of gaining an additional QALY with adjunctive nVNS therapy (vs SoC alone)
^cIndicates that adjunctive nVNS therapy was more effective and cost saving than SoC alone

ISSN: 1129-2377